ArticleEvidence-based complementary and alternative medicine : eCAM2021
Berberine Reduces Renal Cell Pyroptosis in Golden Hamsters with Diabetic Nephropathy through the Nrf2-NLRP3-Caspase-1-GSDMD Pathway.
Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Machine learning for discovering anticancer compounds from plants and elucidating their mechanisms.Journal of computer-aided molecular design · 2026Review
- Astragalus polysaccharides in aquaculture: a comprehensive review on growth, immunity, and disease resistance.Fish physiology and biochemistry · 2026Review
- Exploring betanin regulatory impact on TGF-β and PI3K/AKT pathways in oral cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metabolomic insights into migraine: mechanisms and biomarkers from in vivo and clinical studies.Metabolic brain disease · 2026Review
- Gastroprotective effect of Notoginsenoside R1 On Ethanol-Induced gastric ulcers in Rats via alteration of VEGFR2/ERK and TLR-2/Myd88 signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pharmacological Targeting of NRF2 Represents a Promising Therapeutic Approach for Pyroptosis-Related Non-Alcoholic Fatty Liver Disease.Current medicinal chemistry · 2026Review
- The expression trend and regulatory role of miR-484 in patients with gestational diabetes mellitus.Irish journal of medical science · 2025Article
- NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases.International journal of molecular sciences · 2025Review
- Electroacupuncture Promotes Gastric Motility by Suppressing Pyroptosis via NLRP3/Caspase-1/GSDMD Signaling Pathway in Diabetic Gastroparesis Rats.Chinese journal of integrative medicine · 2025Article
- The molecular mechanism of berberine affecting psoriasis skin inflammation by regulating keratinocyte pyroptosis via the p38 MAPK/NF-κB pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Unveiling the therapeutic potential of berberine: its therapeutic role and molecular mechanisms in kidney diseases.Frontiers in pharmacology · 2025Review
- The serum levels of gasdermin D in uremic patients and its relationship with the prognosis: a prospective observational cohort study.Renal failure · 2024Observational
- Berberine safeguards sepsis-triggered acute gastric damage and inhibits pyroptosis in gastric epithelial cells via suppressing the ubiquitination and degradation of Nrf2.The Kaohsiung journal of medical sciences · 2024Article
- Insights into the Therapeutic uses of Plant Derive Phytocompounds onDiabetic Nephropathy.Current diabetes reviews · 2024Review
- Exploring the role of NLRP3 inflammasome in diabetic nephropathy and the advancements in herbal therapeutics.Frontiers in endocrinology · 2024Review
- A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Identification of pyroptosis-related genes and potential drugs in diabetic nephropathy.Journal of translational medicine · 2023Article
- Natural products in attenuating renal inflammationFrontiers in immunology · 2023Review
- Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism.Frontiers in pharmacology · 2023Review
- Corrigendum to "Berberine Reduces Renal Cell Pyroptosis in Golden Hamsters with Diabetic Nephropathy through the Nrf2-NLRP3-Caspase-1-GSDMD Pathway".Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To observe the effect of berberine (BBR) on kidney cell pyroptosis in golden hamsters with diabetic nephropathy (DN) and to explore the molecular mechanism of its renal protection. Methods: Fifty clean-grade male golden hamsters were randomly divided into a control group (10) and a model building group (40). The DN model was established by high-sugar and high-fat feeding and injection of a small amount of STZ. After successful establishment of the model, they were randomly divided into a model group, western medicine group, and berberine high- and low-dose groups. The western medicine group was given irbesartan 13.5 mg/kg, and the berberine high- and low-dose groups were given BBR 200 mg/kg and 100 mg/kg, respectively, for 8 consecutive weeks. An automatic biochemical analyser was used to measure blood glucose, blood lipids, kidney function, MDA, and other indicators; radioimmunoassay was used to assess serum insulin; enzyme-linked immunosorbent assay (ELISA) was used to quantify IL-1 Results: The kidney tissues of golden hamsters in the control group were normal; Nrf2 was highly expressed, serum MDA level was low, NLRP3 expression in kidney tissue was not obvious, Caspase-1 and GSDMD were weakly expressed, and only a few TUNEL-positive cells were observed. Compared with the control group, the golden hamsters in the model group had obvious renal pathological damage; blood glucose, blood lipids, renal function-related indexes, insulin, and inflammatory factors IL-1 Conclusion: DN golden hamster kidney NLRP3-Caspase-1-GSDMD signalling was enhanced. BBR can reduce oxidative stress damage by regulating antioxidative Nrf2 and then regulating NLRP3-Caspase-1-GSDMD signalling to inhibit pyroptosis, antagonizing DN inflammation-induced damage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.